IDEAYA Biosciences just crossed the line that separates a clinical-stage story from a filing-stage franchise, and the equity debate is no longer whether the lead molecule works in its first metastatic setting. The ASCO late-breaker on the registrational metastatic study showed the darovasertib plus crizotinib combination stretching independently reviewed progression-free survival to 6.9 months against 3.1 months for investigator-chosen immunotherapy. That hazard ratio of 0.42 is the kind of separation rare-tumor programs rarely produce against an active control. The company is now feeding a new-drug application through the Food and Drug Administration real-time oncology review channel, with the filing targeted for completion in the second half of the year. What the market has to decide is whether that win is a contained rare-cancer annuity already reflected in the multiple, or the cash-flow bridge that funds a broader precision-oncology platform.
The mechanism is not mysterious once the biology is named. Uveal melanoma is driven by G-protein pathway mutations that light up protein kinase C, and the combination pairs a selective PKC blocker with a MET inhibitor to shut down the escape route that single-agent PKC blockade leaves open. Immunotherapy, the real-world control, has historically disappointed in this antigen-poor eye cancer, which is why a 37% independently reviewed response rate against a 6% control rate reads as a change in standard rather than a modest add-on. Servier already bought the rights outside the United States last autumn for a $210M upfront plus regulatory and commercial milestones, so the domestic filing is the remaining economic engine. Collaboration revenue in the June quarter was $8.9M of amortized development services, not product sales. The remaining deferred research obligation on that license still sits at $147.0M.
The counterargument is already visible in the same dataset. Overall survival, the endpoint that converts accelerated approval into a durable franchise, was still immature at the January cutoff, and the next formal look is not scheduled until the middle of next year. Duration of response clustered near 6.8 months, which is meaningful in a fast-progressing rare tumor but not the multi-year control that oncology buyers pay peak multiples for. General and administrative expense climbed to $22.5M as commercial hires arrived, and research spending hit $108.7M as the company kept the DLL-three conjugate, the PRMT-five program, and the dual-epigenetic inhibitor all in motion. Net loss widened to $112.5M. A June follow-on plus at-the-market sales rebuilt cash to $1.24B and management still guides a runway into 2030, but that guide assumes the current operating plan, not a fully staffed United States launch plus two new registrational starts.
At a last close of $37.59 the equity capitalizes at about $3.63B. Enterprise value after the mid-year cash pile is about $2.39B. That enterprise value is a high-probability rare-tumor launch plus a call option on antibody-drug conjugates and synthetic-lethality combinations, not a diversified commercial oncology company. Four named variables decide whether that split is fair. Label Breadth asks whether the first approval stays confined to the biomarker-negative metastatic slice or stretches, via the single-arm companion study and guideline inclusion, into the biomarker-positive and neoadjuvant settings. Survival Confirmation asks whether the mid-2027 interim overall-survival look holds the early trend. Second Franchise Conversion asks whether the DLL-three conjugate earns a registrational design by year-end. Commercial Burn Discipline asks whether the pre-launch cost base stays inside the cash guide once a sales force exists. The rest of this report tests those four against the evidence.